|
Durata Therapeutics Announces Preliminary, Topline Phase 3 Clinical Trial Results for Dalbavancin in the Treatment of ABSSSI
February 25, 2013
Drug Tames Refractory AML
December 9, 2012
Advion Announces Full Integration with Agilent Technologies Liquid Chromatography Systems
December 8, 2012
Pfizer To Acquire NextWave Pharmaceuticals
October 22, 2012
NextWave Pharmaceuticals Receives FDA Approval of Quillivant XR™ for Once-Daily Treatment of ADHD
October 1, 2012
Astellas and Ambit Initiate Phase 2b Dose Finding Study of Quizartinib as Monotherapy in Relapsed or Refractory Acute Myeloid Leukemia
June 4, 2012
Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
May 17, 2012
Sanofi Announces FDA Approval of Sklice® Lotion for the Treatment of Head Lice
February 7, 2012
Cempra, Inc. Announces Pricing of Its Initial Public Offering of Common Stock
February 3, 2012
Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at The American Society of Hematology 53rd Annual Meeting
December 1, 2011
Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
November 18, 2011
Quintiles Completes Acquisition of Advion BioServices
November 7, 2011
ZELTIQ Aesthetics, Inc. Prices Initial Public Offering
October 18, 2011
T2 Biosystems Completes $23 Million Series D Financing
August 10, 2011
Pernix Announces Pricing of $28 Million Underwritten Registered Direct Offering of Common Stock
July 21, 2011
Interim Data from Phase 2 Trial of AC220 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia with FLT3-ITD Activating Mutations
June 13, 2011
MAP Pharmaceuticals Submits New Drug Application to FDA for LEVADEX® Orally Inhaled Migraine Drug
May 26, 2011
Advion BioServices Opens Midwest Drug Discovery and Metabolism Center of Excellence
May 23, 2011
ARMGO Pharma Inc., Announces the Appointment of Dr. Sapan Shah as CEO
May 2, 2011
Advion BioServices to Open New Laboratory in Indianapolis to Provide Metabolism, ADME Screening, and Other Early-Stage Bioanalytical Services to Life Sciences Customers, including Lilly
March 1, 2011
Allergan and MAP Pharmaceuticals Announce Collaboration on LEVADEX™ Investigational Therapy for Acute Migraine
January 31, 2011
NextWave Pharmaceuticals Announces Launch of NEXICLON™ XR – First Extended-Release, Once-Daily Clonidine Oral Suspension and Tablet
January 6, 2011
Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
November 5, 2010
Say Goodbye to Unwanted Love Handles: CoolSculpting by Zeltiq™ Receives FDA Clearance for Patented, Non-Invasive Cooling Treatment for Fat Reduction
September 8, 2010
LensAR Laser System™ Receives FDA Clearance for Use in Cataract Surgery
May 18, 2010
Aragon Pharmaceuticals Secures $22 Million in Series B Financing
April 22, 2010
LensAR Strengthens Team with Appointments of Medical Monitor and Two Board Members
April 8, 2010
TRIA Beauty Announces the Launch of the TRIA Skin Clarifying System
April 5, 2010
FDA Grants Permanent Hair Reduction Labeling for Tria Laser Hair Removal System
January 11, 2010
VIVUS Announces Additional Results of Phase 3 avanafil Study in Erectile Dysfunction Showing Efficacy in 15 Minutes
January 11, 2010
Newly Formed Durata Therapeutics Acquires Pfizer’s Vicuron Subsidiary
December 21, 2009
Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications
December 18, 2009
LensAR Inc. to Present Data from Laser Cataract Surgery Clinical Trial at the Annual Meeting of the American Academy of Ophthalmology
October 13, 2009
TransEnterix Secures $55 Million in Financing
October 7, 2009
Novartis gains exclusive worldwide rights to PTK 0796, in Phase III study as potential first-in-class IV and oral broad-spectrum antibiotic
October 08, 2009
Allos Therapeutics' FOLOTYN™ First and Only FDA-Approved Therapy for Relapsed or Refractory Peripheral T-cell Lymphoma
September 25, 2009
Sirion Therapeutics Announces FDA Approval of Zirgan™ (ganciclovir ophthalmic gel) 0.15% for Herpetic Keratitis
September 16, 2009
VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
September 9, 2009
Xanodyne Receives Approval From the U.S. Food and Drug Administration for ZIPSOR™ (diclofenac potassium) Liquid Filled Capsules
June 17, 2009
MAP Pharmaceuticals Phase 3 Trial of LEVADEX™ Migraine Product Candidate Meets All Four Primary Endpoints
May 26, 2009
SkinMedica to Co-promote ACZONE® (dapsone) Gel 5% to Pediatricians in the U.S.
May 11, 2009
Tria Beauty Announces New and Improved Tria Laser Hair Removal System
February 24, 2009
MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints
February 23, 2009
AstraZeneca and MAP Pharmaceuticals Announce Worldwide Collaboration to Develop and Commercialize Unit Dose Budesonide
December 19, 2008
Qnexa Meets Primary Endpoint by Demonstrating Superior Weight Loss over Components and Placebo in the 28-Week Equate Study (OB-301)
December 11, 2008
TRIA Beauty wins as the Prestige Skin Care Breakthrough Product of the Year
December 11, 2008
Ambit Biosciences Presents Data on its Targeted Cancer Therapeutic AC220 for Acute Myeloid Leukemia
December 9, 2008
Two Pralatrexate Studies Presented at the 50th Annual Meeting of the American Society of Hematology
December 6, 2008
Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
October 26, 2008
CeNeRx BioPharma Completes $15 Million Series B Financing
October 17, 2008
Sirion Therapeutics Announces Positive Pivotal Uveitis Data For Durezol™
October 14, 2008
Allure Magazine Names Tria Laser a Beauty Breakthrough Product of 2008
September 17, 2008
Auxilium Pharmaceuticals, Inc. Announces Initiation of XIAFLEX(TM) Phase IIb Study for Peyronie's Disease
September 17, 2008
Stiefel Laboratories Completes Acquisition of Barrier Therapeutics
August 6, 2008
MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine
July 14, 2008
Dynova Laboratories Brings OTC Healhcare Marketing Expertise To Natural Products Market, Acquires “Sinus Buster” Company
July, 2008
Auxilium Pharmaceuticals, Inc. Announces XIAFLEX™ Meets Primary Endpoint With Statistical Significance (p
< 0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture
June 03, 2008
MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics
April 7, 2008
New Microfluidic Technology for Proteomic Research
April 1, 2008
Advion Acquires the Assets of its BioSystems Manufacturing Partner
March 12, 2008
Barrier Therapeutics Announces Top Management Succession Plan
January 25, 2008
CeNeRx BioPharma Announces Successful Completion of Phase 1 Clinical Program for Novel Antidepressant Agent Tyrima™
January 15, 2008
MAP Pharmaceuticals Initiates Phase 3 Clinical Trial of Unit Dose Budesonide in Children with Asthma
January 7, 2008
|
